Cargando…

Oncogene alterations in non-small cell lung cancer—have we MET a new target?

Detalles Bibliográficos
Autores principales:	Dempke, Wolfram C. M., Reuther, Susanne, Hamid, Zohdy, Thoennissen, Nils H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641042/ https://www.ncbi.nlm.nih.gov/pubmed/36386451 http://dx.doi.org/10.21037/tlcr-22-648

Ejemplares similares

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review
por: Dempke, Wolfram C. M., et al.
Publicado: (2021)

We Have Met the Enemy, and It Is Us
por: Johnston, Mark
Publicado: (2013)

Contamination Rate of Cryopreserved Umbilical Cord Blood Is Inversely Correlated with Volume of Sample Collected and Is also Dependent on Delivery Mode
por: Reuther, Susanne, et al.
Publicado: (2022)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Should we SUSPEND MET? Not really
por: Sairam, Krishnamurthy
Publicado: (2016)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

BCKDK alters the metabolism of non-small cell lung cancer
por: Wang, Yanhui, et al.
Publicado: (2021)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer
por: Al Jaberi, Mira, et al.
Publicado: (2023)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth
por: Luraghi, Paolo, et al.
Publicado: (2012)

We have a problem!
por: Jankharia, Bhavin
Publicado: (2008)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Steps We Have Taken and Steps We Must Take
por: Chang, Hyejung, et al.
Publicado: (2016)

Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer
por: Gow, Chien-Hung, et al.
Publicado: (2018)

GOAL: What Have We Learned?
por: Leek, Timothy K Vander
Publicado: (2005)

Oh, the Lessons We Have Learned!
por: Zimmerman, Karen G., et al.
Publicado: (2017)

Have We a Code of Ethics?
Publicado: (1891)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Targeting the Vulnerabilities of Oncogene Activation
por: Huang, Christina, et al.
Publicado: (2023)

Blood Pressure Targets: Will We Reach Definite Figures? I Currently Have Mine
por: Jardim, Paulo César B. Veiga
Publicado: (2017)

Craniofacial genetics: Where have we been and where are we going?
por: Weinberg, Seth M., et al.
Publicado: (2018)

Are we ready to forget everything we have learned during the pandemic?
por: Hernández Ortiz, J.Á.
Publicado: (2022)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

We have a dream… In pursuit of excellence
por: Gopikrishna,
Publicado: (2008)

We have become an Open Access journal!
por: Hotta, Nigishi
Publicado: (2014)

COVID-19: what have we learned?
por: Ho, Yeh-Li, et al.
Publicado: (2020)

Tubercular Mortality: Have We Reached the Limit?
Publicado: (1914)

We have a Responsibility
por: Rajagopal, MR
Publicado: (2016)

Do We Have the Spark?
por: Rupel, Valentina Prevolnik, et al.
Publicado: (2022)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

Sequencing Technologies and Analyses: Where Have We Been and Where Are We Going?
por: Bansal, Vikas, et al.
Publicado: (2019)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Targeting DUBs to degrade oncogenic proteins
por: Cremer, Anjali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jah7fockk6mdhkllkeem6dvai4